LCLucie Curylova

Lucie Curylova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lucie Curylova has a total of 35 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Dysregulation of the p53 pathway provides a therapeutic target in aggressive pediatric sarcomas with stem-like traits

    by Lucie Curylova, Iva Staniczkova Zambo, Jakub Neradil, Michal Kyr, Nicola Jurackova, Sarka Pavlova, Kristyna Polaskova, Peter Mudry, Jaroslav Sterba, Renata Veselska, et al.

    Purpose Pediatric sarcomas are bone and soft tissue tumors that often exhibit high metastatic potential and refractory stem-like phenotypes, resulting in poor outcomes. Aggressive sarcomas frequently harbor a disrupted p53 pathway. However, whether pediatric sarcoma stemness is associated with abrogated p53 function and might be attenuated via p53 reactivation remains unclear. Methods We utilized a unique panel of pediatric sarcoma models and tumor tissue cohorts to investigate the correlation between the expression of stemness-related transcription factors, p53 pathway dysregulations, tumorigenicity in vivo, and clinicopathological features. TP53 mutation status was assessed by next-generation sequencing. Major findings were validated via shRNA-mediated silencing and functional assays. The p53 pathway-targeting drugs were used to explore the effects and selectivity of p53 reactivation against sarcoma cells with stem-like traits. Results We found that highly tumorigenic stem-like sarcoma cells exhibit dysregulated p53, making them vulnerable to drugs that restore wild-type p53 activity. Immunohistochemistry of mouse xenografts and human tumor tissues revealed that p53 dysregulations, together with enhanced expression of the stemness-related transcription factors SOX2 or KLF4, are crucial features in pediatric osteosarcoma, rhabdomyosarcoma, and Ewing’s sarcoma development. p53 dysregulation appears to be an important step for sarcoma cells to acquire a fully stem-like phenotype, and p53-positive pediatric sarcomas exhibit a high frequency of early metastasis. Importantly, reactivating p53 signaling via MDM2/MDMX inhibition selectively induces apoptosis in aggressive, stem-like Ewing’s sarcoma cells while sparing healthy fibroblasts. Conclusions Our results indicate that restoring canonical p53 activity provides a promising strategy for developing improved therapies for pediatric sarcomas with unfavorable stem-like traits.


  • Open Access

    Dysregulation of the p53 pathway provides a therapeutic target in aggressive pediatric sarcomas with stem-like traits

    by Lucie Curylova, Iva Staniczkova Zambo, Jakub Neradil, Michal Kyr, Nicola Jurackova, Sarka Pavlova, Kristyna Polaskova, Peter Mudry, Jaroslav Sterba, Renata Veselska, et al.

    Pediatric sarcomas are bone and soft tissue tumors that often show high metastatic potential and refractory stem-like phenotypes with poor outcomes. Aggressive sarcomas frequently harbor disrupted p53 pathway. However, whether the abrogated p53 function associates with sarcoma stemness which might be targeted by p53 reactivation remains unclear. Here we show that aggressive stem-like sarcoma cells exhibit deregulated p53, making them vulnerable to drugs that restore the wild-type p53 activity. Immunohistochemistry in mice xenografts and human tumor tissues revealed that p53 deregulations together with the enhanced expression of SOX2 or KLF4 stemness-related transcription factors are crucial in the development of pediatric osteosarcoma, rhabdomyosarcoma, and Ewing’s sarcoma. Alteration of p53 function appears to be an important step for attaining a fully stem-like phenotype in sarcoma cells and p53-positive pediatric sarcomas show high frequency of early metastasis. Moreover, the reactivation of p53 via MDM2/MDMX inhibition selectively induces cell death in aggressive stem-like Ewing’s sarcoma cells, while sparing healthy fibroblasts. Collectively, our results demonstrate that restoration of p53 canonical activity may represent a promising strategy for improving therapy of pediatric sarcomas with unfavorable stem-like traits. HIGHLIGHTS SOX2 and KLF4 factors are crucially involved in pediatric sarcoma development Dysregulated p53 pathway predisposes sarcoma cells to a fully stem-like phenotype p53 positivity associates with early metastasis in pediatric sarcoma patients Restoring wild-type p53 activity selectively targets stem-like Ewing’s sarcomas

  • Open Access

    Serotonin limits generation of chromaffin cells during adrenal organ development

    by Polina Kameneva, Victoria I. Melnikova, Maria Eleni Kastriti, Anastasia Kurtova, Emil Kryukov, Aliia Murtazina, Louis Faure, Irina Poverennaya, Artem V. Artemov, Tatiana S. Kalinina, et al.

    Adrenal glands are the major organs releasing catecholamines and regulating our stress response. The mechanisms balancing generation of adrenergic chromaffin cells and protecting against neuroblastoma tumors are still enigmatic. Here we revealed that serotonin (5HT) controls the numbers of chromaffin cells by acting upon their immediate progenitor “bridge” cells via 5-hydroxytryptamine receptor 3A (HTR3A), and the aggressive HTR3Ahigh human neuroblastoma cell lines reduce proliferation in response to HTR3A-specific agonists. In embryos (in vivo), the physiological increase of 5HT caused a prolongation of the cell cycle in “bridge” progenitors leading to a smaller chromaffin population and changing the balance of hormones and behavioral patterns in adulthood. These behavioral effects and smaller adrenals were mirrored in the progeny of pregnant female mice subjected to experimental stress, suggesting a maternal-fetal link that controls developmental adaptations. Finally, these results corresponded to a size-distribution of adrenals found in wild rodents with different coping strategies.